Tresiba Injection, Solution
Product Images NDC 50090-7094

Product Visual Gallery

This gallery contains 63 technical images submitted to the FDA as part of the official labeling for Tresiba (NDC 50090-7094). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Tresiba (Image 01)

Chemical structure diagram of insulin degludec showing its amino acid sequence and molecular components. The diagram illustrates the peptide chains labeled A and B with specific residues and a chemical side chain modification characteristic of insulin degludec.*

FDA Label Image

Figure 2: Mean Gir Profile For 0.4 U/kg Dose Of Tresiba (steady State) In Patients With Type 1 Diabetes Mellitus (Image 02)

A line graph depicting glucose infusion rate (GIR) over time since injection (hours) for insulin degludec at 0.4 U/kg. The x-axis represents hours post-injection up to 42 hours, and the y-axis indicates GIR values. A shaded area highlights the 24-hour interval.*

FDA Label Image

Vial Ifu-1 (Image 03)

An illustration of a medication vial featuring a tamper-resistant cap with a rubber stopper under the cap, indicating packaging designed for secure medication injection.*

FDA Label Image

Vial Ifu-2 (Image 04)

An instructional illustration showing a hand holding a small vial, likely representing the vial of TRESIBA 200 U/mL insulin degludec injection. The image is a simple line drawing depicting the proper way to hold the vial for subcutaneous injection preparation.*

FDA Label Image

Vial Ifu-figure A,b (Image 05)

An instructional illustration showing a hand preparing a vial or pen for injection. The first panel demonstrates holding and manipulating the medical container, and the second panel shows an action related to preparing the injection device, likely removing a cap or attaching a needle. The drawings are simple line art in blue.*

FDA Label Image

Vial Ifu-figure C (Image 06)

An instructional illustration showing hands preparing an injection syringe. The image guides the user to attach a needle or adapt the syringe by pushing down, with a smaller inset showing a close-up of the syringe with needle attached. It is likely related to the use of TRESIBA insulin degludec injection, solution, 200 U/mL.*

FDA Label Image

Vial Ifu-figure D (Image 07)

An instructional illustration showing a hand holding and preparing an injection device, depicting the connection or assembly of the device components prior to use.*

FDA Label Image

Vial Ifu-figure E (Image 08)

An instructional illustration showing the preparation of an injection using a syringe and vial. It depicts a hand holding a vial and another hand drawing liquid from the vial into the syringe with the needle inserted, accompanied by an arrow emphasizing the action.*

FDA Label Image

Vial Ifu-figure F (Image 09)

An instructional line drawing showing a hand holding a syringe vertically with the needle pointing downward into a small cap or stopper, indicated by a large downward arrow. This illustration likely demonstrates a step in the preparation or administration process for an injectable medication.*

FDA Label Image

Vial Ifu-figure G (Image 10)

An illustration showing a hand holding an injection pen upside down with the other hand pointing towards the pen's dosage knob, indicating the step to set or adjust the dose before subcutaneous injection. The image is part of instructional content related to TRESIBA insulin degludec injection.*

FDA Label Image

Vial Ifu-figure H (Image 11)

An instructional illustration showing a person holding a syringe and removing or attaching a component, likely a cap or needle cover. The inset highlights the syringe in detail, focusing on the top portion being handled. This visual guides proper preparation or use of the injection device for subcutaneous administration.*

FDA Label Image

Vial Ifu-figure I (Image 12)

An instructional illustration showing a hand holding an injection vial and a syringe, with an arrow indicating the syringe being inserted into the vial for drawing up medication. The image appears to guide proper injection preparation technique.*

FDA Label Image

Vial Ifu-figure J (Image 13)

An anatomical illustration depicting front and back views of a human figure highlighting recommended subcutaneous injection sites, including the abdomen, outer thighs, upper buttocks, and upper arms.*

FDA Label Image

Vial Ifu-figure K (Image 14)

An instructional illustration showing a hand holding a syringe or pen device and administering a subcutaneous injection into the skin on the forearm. An arrow indicates the injection site and direction.*

FDA Label Image

Vial Ifu-figure L (Image 15)

An instructional illustration showing a hand holding an injection device with an arrow indicating the motion of preparing or administering an injection into the skin on the forearm. The image visually demonstrates a step in a subcutaneous injection process.*

FDA Label Image

Figure A: Novofine Needle Components (Image 16)

An instructional illustration labeled NovoFine showing parts of an insulin needle assembly: outer needle cap, inner needle cap, needle, and paper tab, arranged sequentially from left to right.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 17)

An instructional illustration showing the components of a NovoTwist needle assembly for pen injection. The parts labeled include the outer needle cap, inner needle cap, needle, and paper tab.*

FDA Label Image

Fig. A (Image 18)

An instructional diagram of the TRESIBA FlexTouch insulin injection pen showing labeled parts: pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The pen is green and blue, labeled with TRESIBA and indicates 100 units/mL concentration.*

FDA Label Image

100 U/ml Ifu (Figure B)

An instructional illustration showing a person holding an insulin pen, with a focus on placing or securing a yellow-green cap or component on the pen. This likely demonstrates a step in preparing the pen for injection, relevant for TRESIBA (insulin degludec) injection, solution, subcutaneous use.*

FDA Label Image

100 U/ml Ifu (Figure C)

Illustration showing a hand holding an injection pen device, likely associated with TRESIBA insulin degludec 200 U/mL injection. The pen is oriented horizontally with the needle end pointing right, highlighting proper handling or injection technique.*

FDA Label Image

100 U/ml Ifu (Figure D)

An instructional illustration showing hands holding a NovoFine and NovoTwist device, with arrows indicating direction for a twisting or pulling action. The figure is labeled as Figure D and compares the two device types side by side.*

FDA Label Image

100 U/ml Ifu (Figure E)

An instructional illustration showing the use of NovoFine and NovoTwist components. The image demonstrates a hand gripping the components, indicating the actions needed to prepare or use the injection device for subcutaneous administration.*

FDA Label Image

100 U/ml Ifu (Figure F)

Illustration showing how to connect a NovoFine needle or NovoTwist needle to a syringe or pen device, with directional arrows indicating the attachment process.*

FDA Label Image

100 U/ml Ifu (Figure G)

Instructional illustration showing the attachment process of a NovoFine needle to a NovoTwist insulin pen. Two panels demonstrate aligning and securing the needle onto the pen for use in subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure H)

An instructional illustration showing a hand holding a TRESIBA 200 U/mL injection pen. The image depicts the user selecting a dose of 2 units, indicated on a small dose display window on the pen. The illustration emphasizes the dose selection step in preparing the insulin injection.*

FDA Label Image

100 U/ml Ifu (Figure I)

An instructional illustration showing a hand holding a prefilled pen injector with a yellow label, purportedly preparing for subcutaneous injection. The pen is depicted with motion lines indicating it is being shaken or handled before use.*

FDA Label Image

100 U/ml Ifu (Figure J)

An instructional illustration showing a hand holding a TRESIBA insulin degludec injection pen with a close-up inset of the pen's dial or cap. The image demonstrates the upward motion of the pen indicating how to prepare or operate it for subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure K)

Instructional illustration showing how to select insulin dose units on a TRESIBA insulin pen. It depicts a hand adjusting the dose selector, with examples of 5 units and 24 units chosen on the dose window. The image guides users on dose selection for subcutaneous injection of insulin degludec 200 U/mL.*

FDA Label Image

100 U/ml Ifu (Figure L)

Illustration showing a TRESIBA insulin degludec 200 U/mL injection pen with a dose window indicating approximately 200 units remaining. The pen is shown in a vertical position with a clear dose amount visible on the side.*

FDA Label Image

100 U/ml Ifu (Figure M)

Illustration showing recommended injection sites for subcutaneous administration, highlighting the abdomen, front and outer sides of the thighs, and upper arms on a human figure viewed from front and back.*

FDA Label Image

100 U/ml Ifu (Figure N)

An instructional illustration showing a hand holding a pen-like injection device for TRESIBA (insulin degludec) 200 U/mL. The image depicts the hand grasping the device vertically with an arrow pointing downward, indicating the direction to move or insert the device for subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure O)

An instructional diagram showing a hand holding an insulin pen injector positioned for subcutaneous injection. The diagram includes an inset showing a close-up of the injection needle with a protective cover. A downward arrow indicates the direction to push the injection device to administer the dose.*

FDA Label Image

100 U/ml Ifu (Figure P)

An instructional illustration showing a hand holding a tube with liquid inside, with a speech bubble enumerating the counting sequence "1-2-3-4-5-6." The figure is labeled as "Figure P." It appears to demonstrate counting slowly for a procedure.*

FDA Label Image

100 U/ml Ifu (Figure Q)

An instructional illustration showing a pen-type injector with an arrow pointing upwards, indicating the proper direction to remove or hold the insulin pen. This is part of the usage instructions for TRESIBA injection, insulin degludec 200 U/mL, subcutaneous injection by A-S Medication Solutions.*

FDA Label Image

100 U/ml Ifu (Figure R)

An instructional diagram showing how to attach a NovoFine needle and remove a NovoTwist needle from a pen device. The left panel depicts turning the NovoFine needle in a clockwise direction onto the pen, and the right panel shows pulling the NovoTwist needle straight off the pen.*

FDA Label Image

100 U/ml Ifu (Figure S)

An instructional illustration showing how to attach or disconnect a needle from an injection pen device, with arrows indicating the direction of connection or removal. This diagram is likely part of a user guide for the TRESIBA insulin degludec injection pen.*

FDA Label Image

100 U/ml Ifu (Figure T)

An instructional diagram showing a close-up of hands holding and twisting a green and grey pen cap or cartridge component, intended to demonstrate proper assembly or removal technique for a medication pen device.*

FDA Label Image

Qr Code 100 Units/ml (Image 38)

FDA Label Image

U200 Figure A (Image 39)

An instructional diagram of a TRESIBA (insulin degludec) injection pen showing labeled parts including pen cap, insulin scale, insulin window, dose counter, dose selector, and pen body. The pen label on the body indicates 200 units/mL concentration and highlights the product name and strength clearly.*

FDA Label Image

Figure A: Novofine Needle Components (Image 40)

An instructional diagram showing four components of a NovoFine needle: outer needle cap, inner needle cap, needle, and paper tab. Each part is labeled and visually separated, illustrating the assembly or disassembly of the needle components.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 41)

An instructional illustration labeled NovoTwist showing four components from left to right: an outer needle cap, an inner needle cap, the needle, and a paper tab. Each component is depicted separately for clarity.*

FDA Label Image

200 U/ml Ifu Figure B (Image 43)

An instructional illustration showing two hands adjusting a green ring on a pen-like device, likely demonstrating how to prepare or use the device properly.*

FDA Label Image

200 U/ml Ifu Figure C (Image 44)

An instructional diagram labeled as Figure C shows a close-up view of the tip of a pen-style injection device, presumably for subcutaneous administration, consistent with the insulin degludec injection delivery method.*

FDA Label Image

200 U/ml Ifu Figure D (Image 45)

An instructional illustration labeled 'Figure D' showing a hand holding a NovoFine or NovoTwist needle cap. It demonstrates the action of pulling the needle cap straight off, indicated by arrows pointing away from the needle base.*

FDA Label Image

200 U/ml Ifu Figure E (Image 46)

Instructional illustration showing how to attach a NovoFine needle and a NovoTwist needle to a pen injector for subcutaneous injection. The image depicts hand positioning and twisting motions for proper needle connection.*

FDA Label Image

200 U/ml Ifu Figure F (Image 47)

An instructional illustration labeled Figure F showing the connection of a NovoFine needle to a NovoTwist injection pen. The image uses arrows to guide the user on proper attachment steps for the insulin injection device.*

FDA Label Image

200 U/ml Ifu Figure G (Image 48)

Instructional illustration showing how to assemble a NovoFine or NovoTwist needle onto a syringe or pen device. The diagram indicates the user should attach the needle by twisting or pushing it onto the device, as part of preparing an injection.*

FDA Label Image

200 U/ml Ifu Figure H (Image 49)

An instructional illustration showing a close-up of the TRESIBA injection pen dose selector. The dial is set to 2 units, as indicated by the numeric display. The image depicts hands adjusting the dose on the pen, emphasizing subcutaneous injection use of insulin degludec 200 U/mL.*

FDA Label Image

Figure 3 (Image 52)

Line graph showing the percentage of subjects with an event over 30 months comparing IDeg and IGlar treatments. The x-axis represents time to first event in months, and the y-axis represents the percentage of subjects with an event. The graph includes a hazard ratio with 95% confidence interval (0.91 [0.78; 1.06]).*

FDA Label Image

200 U/ml Ifu Figure I (Image 53)

An instructional illustration showing a hand holding an insulin pen injector filled with medication. The image emphasizes pressing or activating the top of the pen, indicated by motion lines around the thumb area, suggesting preparation or injection steps for the pen device.*

FDA Label Image

200 U/ml Ifu Figure J (Image 54)

An instructional illustration showing a hand holding a TRESIBA injection pen with the dose selector cap being pulled upward. A zoomed-in inset highlights the dose selector cap, indicating how to adjust the insulin degludec injection pen prior to subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure K (Image 55)

An instructional diagram showing a hand holding a TRESIBA (insulin degludec) injection pen with a dose selector. The illustration highlights selecting either 6 units or 24 units of insulin by adjusting the dial on the pen. The image demonstrates dose adjustment features for subcutaneous injection.*

FDA Label Image

200 U/ml Ifu Figure L (Image 56)

An instructional diagram showing a close-up cross-section of a syringe with liquid inside. The syringe barrel is marked with graduations, and the illustration indicates an approximate quantity of 400 units on the left side. The syringe tip has a needle attached, with a transparent protective cap.*

FDA Label Image

200 U/ml Ifu Figure M (Image 57)

An instructional illustration showing front and back views of a human figure with highlighted injection sites for subcutaneous administration, including the abdomen, upper arms, front and outer thighs, and the buttocks area.*

FDA Label Image

200 U/ml Ifu Figure N (Image 58)

An instructional illustration showing a hand holding an injection pen vertically with the needle pointing downward. A large blue arrow below indicates the direction for the injection pen to be moved or positioned. The figure is labeled as 'Figure N'.*

FDA Label Image

200 U/ml Ifu Figure O (Image 59)

An instructional illustration showing a hand holding a pen-like injection device with an arrow pointing downward towards the skin, indicating the action of injecting subcutaneously. A small inset depicts the number '0.3', possibly related to dosage or measurement on the device.*

FDA Label Image

200 U/ml Ifu Figure P (Image 60)

An instructional illustration showing a hand holding a pen-like injection device with the thumb turning the dose selector. A speech bubble instructs to count slowly from 1 to 6, indicating dose setting or injection steps for subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure Q (Image 61)

An illustration showing a pen-style injection device with a blue upward arrow indicating the direction for removing or pulling off the cap, associated with a subcutaneous insulin injection product.*

FDA Label Image

200 U/ml Ifu Figure R (Image 62)

Illustration showing how to prepare the NovoFine and NovoTwist pen needles for use. The images depict the removal and attachment steps of the pen needles, intended for subcutaneous injection with insulin degludec products such as TRESIBA.*

FDA Label Image

200 U/ml Ifu Figure S (Image 63)

An instructional diagram showing the assembly of a pen needle onto an injection pen. It depicts a pen needle positioned next to the tip of the pen, with arrows indicating the direction to attach the needle to the pen for subcutaneous injection use.*

FDA Label Image

200 U/ml Ifu Figure T (Image 64)

Illustration showing a close-up of hands handling a pen-style injection device, specifically demonstrating the removal of a cap from the pen by pulling it away from the body.*

FDA Label Image

Qr Code 200 Units/ml Ifu (Image 65)

FDA Label Image

Label Image (Lbl500907094)

Label for TRESIBA (insulin degludec injection) 200 units/mL, a human prescription drug by A-S Medication Solutions. The label indicates a 3 mL prefilled pen package with dosing information and storage instructions, including avoiding freezing and storing between 36 to 46 degrees Fahrenheit. The NDC number 50090-7094 is visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.